Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Completed 16Recruiting 3Active not recruiting 3Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 37Breast Neoplasms 26Prostatic Neoplasms 22Stomach Neoplasms 12Squamous Cell Carcinoma of Head and Neck 12Lung Neoplasms 11Neoplasms 10Urinary Bladder Neoplasms 8Head and Neck Neoplasms 8Triple Negative Breast Neoplasms 7Neoplasm Metastasis 7Carcinoma, Squamous Cell 6Non-Muscle Invasive Bladder Neoplasms 5Nasopharyngeal Carcinoma 5Carcinoma, Transitional Cell 5Adenocarcinoma 5Oropharyngeal Neoplasms 4Sarcoma 3Prostatic Neoplasms, Castration-Resistant 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Metastatic Castration-resistant Prostate Cancer 3Esophageal Squamous Cell Carcinoma 3Endometrial Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Vaccinia 2Recurrence 2Peritoneal Neoplasms 2Metastatic Castration-Resistant Prostate Cancer 2Melanoma 2

Interventions

pembrolizumab 19Paclitaxel 13Carboplatin 10Pemetrexed 4Cisplatin 4patritumab deruxtecan 3Gemcitabine 3Docetaxel 3Capecitabine 3Albumin-Bound Paclitaxel 3Histamine H2 Antagonists 2Histamine Antagonists 2Dexamethasone 2Acetaminophen 2130-nm albumin-bound paclitaxel 2trastuzumab deruxtecan 1osimertinib 1olaparib 1liposomal doxorubicin 1lenvatinib 1enzalutamide 1cemiplimab 1Vascular Endothelial Growth Factor A 1Serotonin 5-HT3 Receptor Antagonists 1Ramucirumab 1Oxaliplatin 1Neurokinin-1 Receptor Antagonists 1Neoadjuvant Therapy 1Levoleucovorin 1Leucovorin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Parkinson Disease 4, Autosomal Dominant Lewy Body × Docetaxel × Clear all
NCT06952504 2026-05-22

TroFuse-033

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,123 enrolled
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT06989112 2026-05-06

DE-01

AstraZeneca

Phase 3 Recruiting
600 enrolled
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT05142189 2026-04-14

LuCa-MERIT-1

BioNTech SE

Phase 1 Recruiting
320 enrolled
EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡